3278 studies found for:    novartis
Show Display Options
Rank Status Study
21 Completed Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal B Recombinant Vaccine in Adolescents Aged 11-17 Years
Condition: Meningococcal Disease
Interventions: Biological: Meningoccal B recombinat vaccine;   Biological: Meningococcal ACWY-CRM conjugate vaccine and placebo
22 Completed Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
Condition: Influenza
Intervention: Other: Non-intervention observational study
23 Recruiting Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Conditions: Influenza,;   Flu,
Interventions: Biological: Novartis Investigational H5N1 vaccine;   Biological: Novartis Seasonal Influenza Vaccine
24 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + OMV vaccine (rMenB +OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
25 Completed
Has Results
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM + MMRV;   Biological: MMRV;   Biological: MenACWY-CRM
26 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Condition: Meningitis, Meningococcal
Interventions: Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: DTaP-IPV-HBV;   Biological: Hib;   Biological: Rotavirus;   Biological: Pneumococcal 7-valent Conjugate Vaccine;   Biological: HAV;   Biological: MMR-V;   Biological: DTaP
27 Completed Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1);   Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2);   Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3);   Biological: Routine vaccination;   Biological: Meningococcal group C
28 Completed Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: 1a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 1b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 2a - Routine infant vaccinations and rMenB+OMV NZ;   Biological: 2b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations;   Biological: 4a- rMenB+OMV NZ and routine infant vaccinations;   Biological: 4b - rMenB+OMV NZ and routine infant vaccinations
29 Recruiting Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 to 55 Years of Age in the Republic of South Korea
Condition: Meningococcal Disease
Intervention: Biological: Novartis Meningococcal ACWY Conjugate Vaccine
30 Recruiting Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Condition: Meningococcal Meningitis
Intervention: Biological: Meningococcal ACWY conjugate vaccine
31 Completed Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers
Condition: Healthy
Intervention: Drug: Vildagliptin (LAF237)
32 Completed A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
Condition: Prevention of the Meningococcal Disease
Intervention: Biological: rMenB+OMV NZ
33 Recruiting Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: MenACWY-TT
34 Completed
Has Results
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: MenACWY-CRM197;   Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine;   Biological: Hib (Haemophilus influenza b) Vaccine;   Biological: IPV (Inactivated Polio Vaccine) Vaccine;   Biological: Pneumococcal conjugate Vaccine;   Biological: MMR (Measles, Mumps, and Rubella) Vaccine;   Biological: Varicella Vaccine;   Biological: Hepatitis A Virus
35 Completed
Has Results
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
36 Completed
Has Results
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: Novartis MenACWY-CRM;   Biological: Saline Placebo
37 Completed Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Condition: Healthy
Intervention: Biological: Serogroup B meningococcal Vaccine
38 Completed Safety, Tolerability and Immunogenicity of Two Different Formulations of MenB Vaccine, When Administered to Healthy Infants
Condition: Meningococcal Disease
Intervention: Biological: Serogroup B meningococcal Vaccine
39 Completed A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
Condition: Age Related Macular Degeneration (AMD)
Intervention: Device: Health Management Tool (HMT)
40 Completed
Has Results
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM197 (two doses);   Biological: MenC;   Biological: PCV7;   Biological: DTPa-IPV-HepB-Hib;   Biological: MenACWY-CRM197 (one dose)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years